# GLP-1 Drugs for PCOS: Eleven Trials, and Two Analyses That Disagree

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/glp1-for-pcos

> No GLP-1 is approved for PCOS anywhere. The randomized evidence is eleven trials: a low-certainty weight effect, better insulin sensitivity than metformin, and reproductive outcomes two meta-analyses grade differently.

## Key points

- Off-label everywhere: no GLP-1 holds a PCOS indication in any country.
- 2026 review, 11 RCTs: BMI −1.38 kg/m² at low certainty; menstrual regularity “insufficient evidence”.
- 2023 meta, 840 women: natural pregnancy rate RR 1.72 (1.22–2.43).
- The label wants a two-month gap between the last dose and trying to conceive, which is the bind.

No GLP-1 medicine is approved anywhere for polycystic ovary syndrome. Every prescription written for it is off-label, resting on a randomized evidence base that amounts to **eleven trials**.[1] What those trials show is a modest weight effect graded low-certainty, an insulin-sensitivity effect that looks better than metformin’s, and, depending on which analysis you read, either a meaningful improvement in periods and pregnancy rates or not enough evidence to say. Both readings are published. The newer and more careful one is the cautious one.

## What PCOS treatment is aiming at

This matters before any number, because PCOS is not one problem and a drug can help with one part while doing nothing for another. The things people want changed are usually some combination of irregular or absent periods, difficulty conceiving, insulin resistance (sometimes visible as the dark neck patches of [acanthosis nigricans](https://glpwatchdog.org/research/acanthosis-nigricans-and-weight-loss)), excess hair growth, and weight that is unusually hard to shift.

Our [PCOS condition page](https://glpwatchdog.org/conditions/pcos) covers the syndrome itself; this one stays on the drug evidence. Weight loss is the intervention with the longest history here, because losing a relatively small amount often restores ovulation. That is the mechanism through which a weight-loss drug could plausibly help with the reproductive side at all, rather than a direct effect on the ovary. Keep that in mind reading what follows, because it is what the trials are testing.

## What the newest review found

In 2026 the European Journal of Endocrinology published a registered systematic review and meta-analysis of GLP-1 drugs in women with PCOS. It screened 9,654 studies, read 365 in full, and found **11 randomized trials** worth including.[1]

*Eur J Endocrinol 2026, 11 RCTs. Certainty ratings are the review's own.*

| Outcome | Finding | Certainty |
| --- | --- | --- |
| BMI, as an add-on | −1.38 kg/m² (95% CI −2.39 to −0.38) | Low |
| LDL cholesterol, triglycerides | No difference from control | Low |
| Glucose, insulin, hirsutism, menstrual regularity | **Insufficient evidence to conclude** | — |
| Quality of life, mental health, cost-effectiveness | **No studies at all** | — |

The bottom row means *nobody has looked*, which is different from “no benefit found”. For a condition where the psychological burden is a large part of what people want treated, and where cost decides who can have the drug at all, the literature is silent.

> **“Insufficient evidence” is not the same as “does not work”,** and it is not the same as “works” either. It means the trials done so far are too few, too small or too inconsistent to support a conclusion in either direction. The question is open, and a seller who resolves it for you has resolved it without data.

## The analysis that reads more positively

A 2023 meta-analysis in BMC Endocrine Disorders pooled 11 randomized trials covering 840 women and reported something the 2026 review did not: an improvement in the **natural pregnancy rate**, at a risk ratio of 1.72 (95% CI 1.22 to 2.43).[2] It also reported improvements in menstrual cyclicity, insulin sensitivity, body measurements and hormonal indexes. A separate review of weight-lowering drugs and natural fertility found [a single GLP-1 trial](https://glpwatchdog.org/research/one-trial-on-fertility): 80 women, with semaglutide added to metformin raising the pregnancy rate from 15% to 35%. The wider trial record on PCOS and fertility is in our [PCOS and fertility reading list](https://glpwatchdog.org/research/lists/top-glp1-pcos-fertility-studies).

So two pooled analyses of a similar-sized literature reach different levels of confidence about the reproductive outcomes. That is ordinary when the underlying trials are small and measure things differently. The reason to weight the more cautious one is its method, not its date: it registered its protocol in advance and graded the certainty of each finding, which is the machinery that stops a review from reading its own hopes into thin data.

> One analysis reported a natural pregnancy rate 1.72 times that of controls; the registered 2026 review found the menstrual-regularity evidence insufficient to conclude anything.

## Against metformin, which is what most people are already on

Metformin has been the default drug in PCOS for decades, so the practical question is rarely “GLP-1 or nothing”. A 2019 meta-analysis of 8 randomized trials compared them directly.[3] Whether taking the two together adds anything is a separate question, covered in [metformin and a GLP-1 together](https://glpwatchdog.org/research/metformin-and-a-glp1-together).

- **Insulin sensitivity** improved more on a GLP-1 (standardized mean difference −0.40, 95% CI −0.74 to −0.06).
- **BMI** fell further on a GLP-1 (standardized mean difference −1.02, 95% CI −1.85 to −0.19), as did abdominal girth.
- **Nausea and headache** were more common on the GLP-1 than on metformin.
- **Everything else measured** showed no significant difference between them.

The authors’ own summary is that a GLP-1 might be a good choice for women with PCOS and obesity, particularly with [insulin resistance](https://glpwatchdog.org/research/glp1-and-insulin-resistance), and that the available evidence is inconclusive.[3] Both halves are theirs.

## The timing problem

PCOS is among the most common causes of infertility, so a large share of the women taking these drugs for it are doing so because they want to conceive. The Wegovy label puts a number on the gap it wants: **two months**, minimum, between the last dose and trying. Semaglutide clears slowly, and that is why the label sets the interval.[4]

> So the drug that may improve your odds of ovulating is a drug you are meant to be off before you start trying. Nobody has resolved that; it is a sequencing problem, and the person to work it through with is whoever prescribes. Raise it at the first appointment rather than the one where you say you are ready to start trying. Our [preconception timing article](https://glpwatchdog.org/research/glp1-pregnancy-and-trying-to-conceive) works the interval out drug by drug.

There is a second-order version of the same issue. Weight loss can restore ovulation before anyone plans for it, and cycles that were unpredictable for years becoming regular is exactly the situation in which an unplanned pregnancy happens (other period changes on these drugs are in [our period page](https://glpwatchdog.org/research/glp1-and-your-period)). If that is not what you want yet, contraception is part of starting the drug, not a later conversation. If you take an oral contraceptive, our [birth control piece](https://glpwatchdog.org/research/glp1-and-hormonal-birth-control) covers which GLP-1 interferes with it and for how long.

Whoever prescribes, tell them if pregnancy is in your plans, because it changes the timing above. Some services place GLP-1 care inside a women’s or hormone practice. [Hormonally Balanced](https://glpwatchdog.org/reviews/hormonally-balanced), a physician-led women’s hormone practice in Massachusetts, prescribes semaglutide or tirzepatide after a full consultation in the seven states it serves. [Gatlan](https://glpwatchdog.org/reviews/gatlan) runs weight loss as one path in a hormone and longevity clinic, with labs before treatment, and [Joi + Blokes](https://glpwatchdog.org/reviews/joi-and-blokes) began with hormone programs for women and men before adding GLP-1s. Four sellers we track have a page for PCOS itself: [Allara Health](https://glpwatchdog.org/reviews/allara-health) and [PCOS Sisters](https://glpwatchdog.org/reviews/pcos-sisters) build their care around it, and [Gaya Wellness](https://glpwatchdog.org/reviews/gaya-wellness) and [Midi Health](https://glpwatchdog.org/reviews/midi-health) list it among the conditions they treat.

[Twentyeight Health](https://glpwatchdog.org/reviews/twentyeight-health), a women’s health service best known for birth control, offers a Weight Care program in 22 states: a $19.99 Complete Care membership covers provider visits and messaging, and FDA-approved GLP-1s such as Wegovy are billed separately by the pharmacy, often through insurance or Medicaid.

[Alloy](https://glpwatchdog.org/reviews/alloy) and [Steady State Health](https://glpwatchdog.org/reviews/steady-state-health) are built around midlife and menopause care rather than PCOS, so check the fit before you sign up. [Eve](https://glpwatchdog.org/reviews/eve) and [Nurx](https://glpwatchdog.org/reviews/nurx) are women’s telehealth brands, and Eve sells compounded GLP-1s beside brand Ozempic, Wegovy and Mounjaro, but neither lists a PCOS program on its site. [Tru2u](https://glpwatchdog.org/reviews/tru2u), an Oregon women’s wellness brand, lists compounded semaglutide and tirzepatide as injections or oral tablets. To compare sellers on price and licensure, our [semaglutide board for PCOS](https://glpwatchdog.org/best/semaglutide-providers/for-pcos) and [the tirzepatide version](https://glpwatchdog.org/best/tirzepatide-providers/for-pcos) rank every one we track, with the figures from these reviews set beside the list.

## What nobody can tell you yet

- **Whether it helps the symptoms you may care about most.** Hirsutism and menstrual regularity both sit in the insufficient-evidence column of the newest review.[1]
- **Whether it helps how you feel.** No trial has measured quality of life or mental health in this population at all.[1]
- **What happens long term.** The trials are short; PCOS is not.
- **Whether it is worth the money for you.** No cost-effectiveness study exists,[1] and off-label use makes coverage harder. Our [insurance section](https://glpwatchdog.org/insurance) tracks what plans publish and the [prior authorization letter generator](https://glpwatchdog.org/tools/glp1-prior-auth-letter-generator) assembles a submission.

## Frequently asked questions

### Is any GLP-1 approved for PCOS?

No. Every prescription written for polycystic ovary syndrome is off-label, in any country. The randomized evidence base is eleven trials, and a 2026 systematic review rated the weight effect low-certainty and found the evidence on menstrual regularity insufficient to draw a conclusion.

### Does a GLP-1 make periods regular again in PCOS?

The evidence disagrees with itself. A 2023 meta-analysis of 840 women reported improved menstrual cyclicity and a natural pregnancy rate 1.72 times that of controls. A registered 2026 systematic review of 11 randomized trials judged the menstrual-regularity evidence insufficient to support a conclusion. Both are published; the more cautious one registered its protocol in advance and graded the certainty of each finding.

### Is a GLP-1 better than metformin for PCOS?

On two measures, in one 2019 meta-analysis of 8 trials: insulin sensitivity and BMI both improved more on a GLP-1, along with abdominal girth. Nausea and headache were more common. Everything else measured showed no significant difference, and the authors called the overall evidence inconclusive.

### Can I take a GLP-1 while trying to conceive?

The Wegovy label asks you to come off it at least two months ahead of trying to conceive, since semaglutide is slow to leave the body. When fertility is the whole reason for taking it, that ordering has to be planned deliberately. Bring it up when you start the drug, not when you want to stop.

### Will it help the excess hair growth?

Nobody can say. Hirsutism is one of the outcomes the 2026 systematic review placed in its insufficient-evidence column, meaning the trials to date are too few or too inconsistent to support a conclusion either way.

## References

1. Forslund M, Wändell P, Forsberg L, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome — a systematic review and meta-analysis. European Journal of Endocrinology. 2026. PMID: 41701618. https://pubmed.ncbi.nlm.nih.gov/41701618/
2. Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocrine Disorders. 2023. PMID: 37940910. https://pubmed.ncbi.nlm.nih.gov/37940910/
3. Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reproductive BioMedicine Online. 2019. PMID: 31229399. https://pubmed.ncbi.nlm.nih.gov/31229399/
4. Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 8.3 Females and Males of Reproductive Potential (revised 06/2026). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

---

Cite as: GLP Watchdog, Ruth Calder, "GLP-1 Drugs for PCOS: Eleven Trials, and Two Analyses That Disagree", published 2026-08-19, updated 2026-11-02. https://glpwatchdog.org/research/glp1-for-pcos

Canonical HTML page: https://glpwatchdog.org/research/glp1-for-pcos

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
